Диссертация (1139439), страница 38
Текст из файла (страница 38)
9: 444-449, 1956.138. Capsoni F., Matteo Longhi M., Weinstein R. Bisphosphonate-associatedosteonecrosis of the jaw: the rheumatologist’s role // Arthritis Research & Therapy2006, 8:219 (doi:10.1186/ar2050)139. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of thejaw: a possible association.
Med J Aust. 2005;182:413-5. [PMID: 15850439]140. Cartsos V.M., Zhu S., Zavras A.I. Bisphosphonate Use and the Risk of AdverseJaw Outcomes: A medical claims study of 714,217 people // J Am Dent Assoc2008;139;23-30141. Catterall J.B., Cawston T.E. Drugs in development: bisphosphonates andmetalloproteinase inhibitors // Arthritis Res Ther 2003, 5:12-24312142. Cheng A., Mavrokokki A., Carter G., Stein B., Fazzalari NL, Wilson DF, GossAN The dental implications of bisphosphonates and bone disease // Australian DentalJournal Medications Supplement 2005;50:4.143. Chiandussi S, Biasiotto M, Dore F, Cavalli F, Cova MA, Di Leonarda R.
Clinicaland diagnostic imaging of bisphosphonate- associated osteonecrosis of the jaws.Dentomaxillofac Radiol. 2006;35:236–243.144. Coleman R.E. Risks and benefits of bisphosphonates // British Journal of Cancer(2008) 98, 1736 – 1740145. Conte P, Guarneri V: Safety of intravenous and oral bisphosphonates andcompliance with dosing regimens. Oncologist 2004, Suppl 4:28-37.146. Corso A, Varettoni M, Zappasodi P, et al. A different schedule of zolendronicacid can reduce the risk of the osteonecrosis of the jaw in patients with multiplemyeloma. Leukemia 2007;21:147. Cossío P.I., Macián A.C., Pérez Ceballos J.L., Nicas J.P., Gutiérrez Pérez J.L.Bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma //Med Oral Patol Oral Cir Bucal.
2008 Jan1;13(1):E52-57.148. Coxon FP, Benford HL, Russell RGG, Rogers MJ: Protein synthesis is requiredfor caspase activation and induction of apoptosis by bisphosphonate drugs. MolPharmacol 1998, 54: 631-638.149. Deftos LJ (2005). Treatment of Paget's disease—taming the wild osteoclast.
NEngl J Med 353:872-875.150. Dimopoulos M, Kastritis E, Moulopoulos LA, Melakopoulos I, et al. Theincidence of osteonecrosis of the jaw in patients with multiple myeloma who receivebisphosphonates depends on the type of bisphosphonate. Blood. (American Society ofHematology Annual Meeting Abstracts) 106:637, 2005151. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D,Moulopoulos LA, Bamia C, Terpos E, Tsionos K, Bamias A 2006 Osteonecrosis of thejaw in patients with multiple myeloma treated with bisphosphonates: Evidence ofincreased risk after treatment with zoledronic acid. Haematologica 91:968–971.313152.
Dixon RB, Tricker ND, Garetto LP. Bone turnover in elderly canine mandibleand tibia [abstract 2579]. J Dent Res. 1997;76:336153. DrugTopics.Top200brand-namedrugsbyunits“www.drugtopics.com/drugtopics/Pharmacy+Facts+And+Figures/in2006.Top-200-brand-name-drugs-by-units-in-2006/ArticleStandard/Article/detail/407649?contextCategoryId=7604”. Accessed Sept. 12, 2007154. Dunford JE, Thompson K, Coxon FP, et al.
Structureactivity relationships forinhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption invivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296:235—242.155. Durie BG, Katz M, Crowley J: Osteonecrosis of the jaw and bisphosphonates. NEngl J Med 2005, 353:99-102.156. Edwards B.J., Hellstein J.W., Jacobsen P.L., Kaltman S., Mariotti A., MiglioratiC.A. Updated recommendations for managing the care of patients receiving oralbisphosphonate therapy // J Am Dent Assoc 2008;139;1674-1677157.
Eisenbud L, Miller J, Roberts IL. Garré's proliferative periostitis occurringsimultaneously in four quadrants of the jaws. Oral Surg Oral Med Oral Pathol. 1981Feb;51(2):172-8.158. EL-MoFTY, S.: Chronic diffuse sclerosing osteomyelitis. Oral Surg. 1973: 36:898-904159. Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect ofalendronate continuation versus discontinuation in women with low BMD: results fromthe Fracture Intervention Trial long-term extension.
J Bone Miner Res 2004;19:125969.160. Estilo CS, Van Poznak CH, Williams T, Evtimovska E, Tkach L, Halpern JL, etal. Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates:a retrospective study [Abstract]. Proc Am Soc Clin Oncol.2004;22:750.161. EVANS, B. E., JACOBSON, J. H., PEIRCE, E. C., FRIEDMAN, E. W.
&SCHWARTZ, A E.: Chronic osteomyelitis of mandible. Hyperbaric oxygenationtreatment. N. Y. State J. Med. 1976: June: 966-967.314162. Eyrich GK, Baltensperger MM, Bruder E, Graetz KW. Primary chronicosteomyelitis in childhood and adolescence: a retrospective analysis of 11 casesandreview of the literature. J Oral Maxillofac Surg. 2003 May;61(5):561-73.163. Farah CS, Savage NW. Oral ulceration with bone sequestration. Aust Dent J2003;48(1):61-64.164. Felsberg GJ, Gore RL, Schweitzer ME, Jui V. Sclerosing osteomyelitis of Garrè(periostitis ossificans). Oral Surg Oral Med Oral Pathol. 1990 Jul;70(1):117-20.165.
Ficarra G, Beninati F, Rubino I, et al. Osteonecrosis of the jaws in periodontalpatients with a history of bisphosphonates treatment. J Clin Periodontol. 2005;32:1125–1128.166. Ficarra G, Beninati F, Rubino I, Vannucchi A, Longo G, Tonelli P, et al.Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonatestreatment. J Clin Periodontol. 2005;32:1123-8. [PMID: 16212571]167. Ficarra G., Beninati F. Bisphosphonate-related Osteonecrosis of the Jaws: AnUpdate on Clinical, Pathological and Management Aspects // Head and Neck Pathol(2007) 1:132–140168. Fisher JE, Rodan GA, Reszka AA: In vivo effects of bisphosphonates on theosteoclast mevalonate pathway.
Endocrinology 141:4793-4796, 2000169. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ,Wesolowski G, Russell RGG, Rodan GA, Reszka AA: Alendronate mechanism ofaction: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibitionof osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl AcadSci USA 1999, 96:133-138.170. Fleisch H. Bisphosphonates: mechanisms of action.
Endocr Rev. 1998;19:80—100.171. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002;4:30-34.172. Fondi С., Franchi А. Definition of bone necrosis by the pathologist // ClinicalCases in Mineral and Bone Metabolism 2007; 4(1): 21-26315173. Font R.G., Martínez García M.L., Olmos Martínez J.M. Osteochemonecrosis ofthe Jaws due to Bisphosphonate Treatments.
Update // Med Oral Patol Oral Cir Bucal.2008 May1;13(5):E318-24.174. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis invitro and testosterone-stimulated vascular regrowth in the ventral prostate in castratedrats. Cancer Res 2002;62:6538-44.175. Garcia-Marin F, Iriarte-Ortabe JI, Reychler H: Chronic diffuse sclerosingosteomyelitis of the mandible or mandibular location of SAPHO syndrome. ActaStomatol Belg 93:65, 1996176. Gibbs SD, O’Grady J, Seymour JF, Prince HM.
Bisphosphonate-inducedosteonecrosis of the jaw requires early detection and intervention [Letter]. Med J Aust.2005;183:549-50. [PMID: 16296983]177. Glahn M. The surgical treatment of chronic osteomyelitis of the mandible. JMaxillofac Surg 1974;2:238-41.178. Glass DA II, Patel MS, Karsenty G (2003). A new insight into the formation ofosteolytic lesions in multiple myeloma. N Engl J Med 349:2479-2480.179. Glick M. Closing in on the puzzle of ONJ // J Am Dent Assoc 2008 139: 12-15180.
Gnepp D.R. Diagnostic Surgical Pathology of the Head and Neck. – 2nd ed.181. GORMAN JM. Periostitis ossificans; report of a case. Oral Surg Oral Med OralPathol. 1957 Feb;10(2):129-32.182. Gorman. J. M.: Periostitis Ossificans, ORAL SURG. 10: 129-132, 1957Monteleone, L., and Hagy, D. M.: Garre’s Osteomyelitis, J. Oral Burg. 20: 423-431,1962.183. Grbic JT, Landesberg R, Lin SQ, et al. Incidence of osteonecrosis of the jaw inwomen with postmenopausal osteoporosis in the Health Outcomes and ReducedIncidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial. JADA2008;139(1):32-40.184.
Grey A., Reid I.R. Differences between the bisphosphonates for the preventionand treatment of osteoporosis // Therapeutics and Clinical Risk Management 2006:2(1)77– 86316185. GrimePD,BowermanJE,WellerPJ.Gentamicinimpregnatedpolymethylmethacrylate (PMMA) beads in the treatment of primary chronicosteomyelitis of the mandible. Br J Oral Maxillofac Surg 1990;28:367-74.186. Groot RH, van Merkesteyn JP, Bras J: Diffuse sclerosing osteomyelitis and floridosseous dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 81:333, 1996187. Groot RH, van Merkesteyn JP, van Soest JJ, Bras J. Diffuse sclerosingosteomyelitis (chronic tendoperiostitis) of the mandible. An 11-year follow-up report.Oral Surg Oral Med Oral Pathol. 1992 Nov;74(5):557-60.188.
Guo R-T, Cao R., Liang P-H., Ko T-P., Chang T-H., Hudock M.P., Jeng W-Y.,Chen C. K.-M., Zhang Y., Song Y., Kuo C-J., Yin F., Oldfield E., Wang A. H.-J.Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases // PNAS.2007 104(24):10022-7189. Hall HD, Jacobs JS, O’Malley JP. Necrosis of maxilla in patient with herpeszoster. Report of a case.Oral Surg Oral Med Oral Pathol 1974;37:657–662. [PubMed:4524373]190. Han ZH, Palnitkar S, Rao DS, et al: Effects of ethnicity and age or menopause onthe remodeling and turnover of iliac bone: Implications for mechanisms of bone loss.
JBone Miner Res 12:498, 1997191. Hansen T, Kunkel M, Weber A, James Kirkpatrick C: Osteonecrosis of the jawsin patients treated with bisphosphonates—histomorphologic analysis in comparisonwith infected osteoradionecrosis. J Oral Pathol Med 2006;35:155–160.192. Hauge EM, Qvesel D, Eriksen EF, Mosekilde L, Melsen F. Cancellous boneremodeling occurs in specialized compartments lined by cells expressing osteoblasticmarkers.
J Bone Miner Res 2001;16: 1575-8193. Head MD, Sanger JR, Matloub HS, Yousif NJ, Rooney GE. Bilateralmicrovascular free iliac grafts for mandibular reconstruction in intractableosteomyelitis. J Oral Maxillofac Surg 1986;44:724-7.194. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw):is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005;63:682-689.317195. Hermans R, Fossion E, Ioannides C, Van de Bogaert W, Ghekiere J, Baert AL.CT fi ndings in osteoradionecrosis of the mandibule. Skeletal Radiol. 1996;25:31–36.196.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
